Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, February 4, 2024

Spider venom molecule meets benchmarks to treat heart attack and stroke

 There is a venom library. What the fuck are our stroke researchers doing with this to help with stroke recovery? There is already this out there:

Snake Venom Helps Hydrogels Stop the Bleeding

Intravenous Ancrod for Treatment of Acute Ischemic Stroke

Biting back - snake venom contains toxic clotting factors

 


Snake Venom Could Hold Key To Alzheimer’s Breakthrough


Metrion taps Venomtech’s venom library for ion channel modulator discovery

The latest here:

Spider venom molecule meets benchmarks to treat heart attack and stroke

A spider venom molecule being investigated by a University of Queensland team has met critical benchmarks towards becoming a treatment for heart attack and stroke.

Associate Professor Nathan Palpant and Professor Glenn King from UQ's Institute for Molecular Bioscience have previously shown that the drug candidate Hi1a protects cells from the damage caused by heart attack and stroke.

Dr Palpant said a subsequent study has put the drug through a series of preclinical tests designed to mimic real-life treatment scenarios.

These tests are a major step towards helping us understand how Hi1a would work as a therapeutic – at what stage of a heart attack it could be used and what the doses should be.

We established that Hi1a is as effective at protecting the heart as the only cardioprotective drug to reach Phase 3 clinical trials, a drug that was ultimately shelved due to side effects.

Importantly, we found that Hi1a only interacts with cells in the injured zone of the heart during an attack and doesn't bind to healthy regions of the heart – reducing the chance of side effects."

Dr. Nathan Palpant, Associate Professor, UQ's Institute for Molecular Bioscience

Professor King, who recently won the Prime Minister's Prize for Innovation for developing the world's first insecticides from spider venom, discovered Hi1a in the venom of the K'gari funnel web spider.

"Hi1a could reduce damage to the heart and brain during heart attacks and strokes by preventing cell death caused by lack of oxygen," Professor King said.

"Our testing and safety studies from independent contract research organisations has provided evidence that Hi1a could be an effective and safe therapeutic."

Infensa Bioscience, a company co-founded by the researchers, raised $23 million in 2022 to develop Hi1a for commercial purposes.

Infensa CEO and UQ researcher, Associate Professor Mark Smythe, said cardiovascular disease is the leading cause of death globally.

"Most deaths from cardiovascular disease are caused by heart attacks and strokes, yet there are no drugs on the market that prevent the damage they cause," Dr Smythe said.

"An effective drug to treat heart attacks would have worldwide impact, providing a breakthrough to improve the lives of millions of individuals living with heart disease."

The research team included Dr Meredith Redd from IMB as well as Dr Melissa Reichelt and Dr Yusuke Yoshikawa from UQ's School of Biomedical Sciences.

The study was published in the world's leading cardiac journal The European Heart Journal.

Source:
Journal reference:

Redd, M. A., et al. (2023). Acid-sensing ion channel 1a blockade reduces myocardial injury in rodent models of myocardial infarction. European Heart Journal. doi.org/10.1093/eurheartj/ehad793.

No comments:

Post a Comment